Rare diseases
Investigational molecules
Locations
706 conditions with trials, the busiest first
3 924 trials across Europe, recruiting first
Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer
AustriaStudy of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease
AustriaStudy of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer
BelgiumStudy of Niraparib and Dostarlimab with Radiotherapy for Patients with Locally-Advanced Head and Neck Cancer
SpainStudy on Darolutamide and Capecitabine for Patients with Advanced Triple-Negative Androgen Receptor Positive Breast Cancer
FranceStudy Comparing Radiotherapy Alone to Radiotherapy with Cisplatin for Patients with Sinus or Salivary Gland Tumors
BelgiumStudy of Cabozantinib and Atezolizumab Compared to Hormonal Therapy in Adults with Metastatic Castration-Resistant Prostate Cancer
BelgiumStudy of Belantamab Mafodotin Alone and with Drug Combination for Patients with Relapsed/Refractory Multiple Myeloma
FranceStudy of Pembrolizumab with Cisplatin or Carboplatin and Pemetrexed for Patients with Resectable Malignant Pleural Mesothelioma
ItalyStudy on Atezolizumab and Resiquimod Sulfate with Radiotherapy for Patients with Advanced Solid Tumors
FranceStudy of Fibrinogen Treatment for Bleeding in Patients with Blood Cancer and Low Platelet Count Who Do Not Respond to Platelet Transfusions
FranceStudy on Pembrolizumab and Olaparib for Patients with Resectable Soft Tissue Sarcoma
FranceThe therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
